204067-01-6
204067-01-6 structure
- Name: PD 176252
- Chemical Name: (2S)-3-(1H-indol-3-yl)-N-[[1-(5-methoxypyridin-2-yl)cyclohexyl]methyl]-2-methyl-2-[(4-nitrophenyl)carbamoylamino]propanamide
- CAS Number: 204067-01-6
- Molecular Formula: C32H36N6O5
- Molecular Weight: 584.66500
- Catalog: Signaling Pathways GPCR/G Protein Bombesin Receptor
- Create Date: 2016-07-15 12:52:55
- Modify Date: 2024-02-04 08:28:01
-
PD176252 is a potent antagonist of neuromedin-B preferring (BB1) and gastrin-releasing peptide-preferring (BB2) receptor with Kis of 0.17 nM and 1 nM for human BB1 and BB2 receptors, and 0.66 nM, 16 nM for Rat BB1 and BB2 receptors, respectively; PD176252 is also an agonist of N-Formyl peptide receptor1/2 (FPR1/FPR2), with EC50s of 0.31 and 0.66 μM in HL-60 cells.
| Name | (2S)-3-(1H-indol-3-yl)-N-[[1-(5-methoxypyridin-2-yl)cyclohexyl]methyl]-2-methyl-2-[(4-nitrophenyl)carbamoylamino]propanamide |
|---|---|
| Synonyms |
7-Chlorokynurenic acid
PD176252 |
| Description | PD176252 is a potent antagonist of neuromedin-B preferring (BB1) and gastrin-releasing peptide-preferring (BB2) receptor with Kis of 0.17 nM and 1 nM for human BB1 and BB2 receptors, and 0.66 nM, 16 nM for Rat BB1 and BB2 receptors, respectively; PD176252 is also an agonist of N-Formyl peptide receptor1/2 (FPR1/FPR2), with EC50s of 0.31 and 0.66 μM in HL-60 cells. |
|---|---|
| Related Catalog | |
| Target |
Ki: 0.17 nM (Human BB1 receptor), 0.66 nM (Rat BB1 receptor), 1 nM (Human BB2 receptor), 16 nM (Rat BB2 receptor)[1] EC50: 0.31 μM (FPR1), 0.66 μM (FPR2)[2] |
| In Vitro | PD176252 is a potent antagonist of neuromedin-B preferring (BB1) and gastrin-releasing peptide-preferring (BB2) receptor with Kis of 0.17 nM and 1 nM for human BB1 and BB2 receptors, and 0.66 nM, 16 nM for Rat BB1 and BB2 receptors, respectively. PD176252 inhibits acidification responses to neuromedin-B or neuromedin-C at the human BB1 or BB2 receptors expressed in CHO cells, with the appKBs of 4.0 nM or 13 nM, and blocks bombesin-evoked increases in intracellular calcium levels in CHO cells stably expressing human BB1 or BB2 receptors, with appKBs of 2.3 nM and 36 nM, respectively. PD176252 is also an agonist of N-Formyl peptide receptor1/2 (FPR1/FPR2), with EC50s of 0.31 and 0.66 μM in HL-60 cells. PD176252 activates Ca2+ mobilization in HL-60 cells transfected with human FPRs (EC50, 0.72 ± 0.21 μM)[2]. PD176252 inhibits little specific 125I-gastrin releasing peptide binding to NCI-H345 cells at 1 nM and suppresses almost all specific bindings at 1000 nM, with an IC50 of 30 nM. PD176252 (10, 30 μM) significantly inhibits the growth of NCI-H345 or H1299 cells, with IC50s of 7 and 5 μM[3]. |
| In Vivo | PD176252 (1, 10 μg, p.o.) potently inhibits the growth of the proliferation of NCI-H1299 xenografts in nude mice[3]. |
| Cell Assay | Growth studies in vitro are conducted using the MTT colorimetic assays. NCI-H1299 cells (104/well) are placed in SIT medium and various concentrations of PD176252 or PD168368 added. After 4 days, MTT is added. After 4 h, 150 μL of DMSO is added. After 16 h, the optical density at 570 nm is determined[3]. |
| Animal Admin | Mice[3] Female athymic Balb/c nude mice, 4-5 weeks old, are housed in a pathogen-free temperature controlled isolation room, with a diet consisting of autoclaved rodent chow and autoclaved water given ad libitum. NCI-H1299 cells (1×107) are injected into the right flank of each mouse by subcutaneous injection. Palpable tumors are observed in approximately 90% of the mice after 1 week. Polyethylene glycol (PEG, 100 μL) or PD176252 (10 or 1 μg in 100 μL of PEG 400) are injected daily by gavage. The tumor volume (height×width×depth) is determined weekly by calipers and recorded[3]. |
| References |
| Molecular Formula | C32H36N6O5 |
|---|---|
| Molecular Weight | 584.66500 |
| Exact Mass | 584.27500 |
| PSA | 153.96000 |
| LogP | 6.99890 |
| Storage condition | 2-8℃ |